- Home
- NRSN vs ASBP Comparison
NRSN vs ASBP Comparison
Compare NRSN & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- ASBP
- Stock Information
- Founded
- NRSN 2017
- ASBP 2021
- Country
- NRSN Israel
- ASBP United States
- Employees
- NRSN N/A
- ASBP N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- ASBP Health Care
- Exchange
- NRSN Nasdaq
- ASBP Nasdaq
- Market Cap
- NRSN 26.0M
- ASBP 26.6M
- IPO Year
- NRSN 2021
- ASBP N/A
- Fundamental
- Price
- NRSN $1.18
- ASBP $0.45
- Analyst Decision
- NRSN Buy
- ASBP
- Analyst Count
- NRSN 2
- ASBP 0
- Target Price
- NRSN $14.00
- ASBP N/A
- AVG Volume (30 Days)
- NRSN 1.4M
- ASBP 4.7M
- Earning Date
- NRSN 09-17-2025
- ASBP 08-13-2025
- Dividend Yield
- NRSN N/A
- ASBP N/A
- EPS Growth
- NRSN N/A
- ASBP N/A
- EPS
- NRSN N/A
- ASBP N/A
- Revenue
- NRSN N/A
- ASBP N/A
- Revenue This Year
- NRSN N/A
- ASBP N/A
- Revenue Next Year
- NRSN N/A
- ASBP N/A
- P/E Ratio
- NRSN N/A
- ASBP N/A
- Revenue Growth
- NRSN N/A
- ASBP N/A
- 52 Week Low
- NRSN $0.80
- ASBP $0.22
- 52 Week High
- NRSN $2.60
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- NRSN 46.42
- ASBP 47.54
- Support Level
- NRSN $1.14
- ASBP $0.41
- Resistance Level
- NRSN $1.28
- ASBP $0.47
- Average True Range (ATR)
- NRSN 0.15
- ASBP 0.05
- MACD
- NRSN 0.03
- ASBP -0.02
- Stochastic Oscillator
- NRSN 22.33
- ASBP 35.56
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.